TRxADE HEALTH (MEDS) stock gained 28% during regular trading on October 1, 2026, after the company's Corexa Pharmacy division surpassed $1 million in monthly revenue for the first time. The healthcare technology firm saw its shares rise to $4.11 from the prior close of $3.21, with trading volume reaching approximately 3.78 million shares.
What happened
On October 1, 2026, TRxADE HEALTH announced via ACCESS Newswire that DataMeds AI's Corexa Pharmacy division crossed the $1 million monthly revenue threshold. The milestone marks a significant inflection point for the company's pharmacy operations, which focus on digitally enhancing drug acquisition and pricing transparency for retail pharmacies.
Corexa Health operates as a pharmacy services division within the broader TRxADE HEALTH ecosystem. The company, formerly known as Trxade Group, rebranded in June 2021 and has been expanding its technology-driven pharmacy solutions. The Corexa Pharmacy revenue achievement comes amid a series of recent initiatives, including the launch of the "Health Lives Here" mobile application developed with Tollo Health, which was unveiled in late September 2026.
The announcement follows the company's May 2026 10-Q filing with the Securities and Exchange Commission, which provided financial disclosures for the second quarter. TRxADE HEALTH also completed its NASDAQ Capital Markets listing under the MEDS ticker in late July 2026.
Why the stock moved
The stock moved on the Corexa Pharmacy revenue milestone because it represents a concrete financial achievement that validates the company's pharmacy technology strategy. Reaching $1 million in monthly revenue is a measurable proof point for a company with a market capitalization of roughly $7.19 million, suggesting meaningful commercial traction relative to its size.
The announcement published by ACCESS Newswire on October 1, 2026, at 10:02 AM ET provided the market with the specific catalyst. Prior news in late September had highlighted the launch of the "Health Lives Here" mobile application in partnership with Tollo Health and the NFL Alumni Association, which built investor interest in the company's mobile health initiatives.
Additionally, a September 18, 2026, ACCESS Newswire release noted that a litigation settlement extinguished approximately $19 million in liabilities and retired 364,099 common shares, strengthening the company's balance sheet. However, the October 1 revenue milestone served as the direct catalyst for this trading session's move.
The numbers
TRxADE HEALTH reported the following session metrics on October 1, 2026:
- Session gain: 28.04%
- Closing price: $4.11
- Prior close: $3.21
- Session volume: 3,777,348 shares
- Market capitalization: $7.19 million
- Shares outstanding: 1,750,060
- Average daily volume (short interest data): 6,603,130 shares
The company's float stands at approximately 734,537 shares, based on data through July 2026. The short interest of 430,628 shares represents roughly 1.00 days to cover, indicating elevated short interest relative to trading volume.
[CHART_BLOCK]
What to watch
Investors should monitor whether Corexa Pharmacy can sustain and grow beyond the $1 million monthly revenue milestone in subsequent periods. The company's ability to expand its pharmacy membership base and increase transaction volume on the TRxADE marketplace will be key metrics to track.
The "Health Lives Here" mobile application, launched in partnership with Tollo Health and backed by the NFL Alumni Association, represents a broader consumer-facing strategy. TRxADE HEALTH has been positioning itself at the intersection of telehealth and pharmacy services, but execution on these initiatives will determine whether recent momentum continues.
The company's 8-K filings from September and August 2026, along with the May 2026 10-Q, provide regulatory documentation for investors seeking detailed financial and operational disclosures. TRxADE HEALTH's continued listing on NASDAQ Capital Markets following its July 2026 debut also warrants attention for liquidity and regulatory compliance considerations.
For the latest quote, filings, and news on TRxADE HEALTH, visit MEDS on Vantafin.